Defective lipid metabolism in neurodegeneration with brain iron accumulation (NBIA) syndromes: not only a matter of iron

Journal of Inherited Metabolic Disease

Volumn 38, Issue 1, 2015, Pages 123-136

  Colombelli, Cristina ^a   Aoun, Manar ^a   Tiranti, Valeria ^a  

^a DEPARTMENT OF NEUROSURGERY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A SYNTHASE; IRON; PHOSPHOLIPID; SPHINGOLIPID; FATTY ACID; MIXED FUNCTION OXIDASE;

ARTICLE; AUTOPHAGY; AUTOSOMAL DOMINANT DISORDER; CHROMOSOME DISORDER; COASY PROTEIN ASSOCIATED NEURODEGENERATION; FATTY ACID HYDROXYLASE ASSOCIATED NEURODEGENERATION; FATTY ACID METABOLISM; HUMAN; IRON METABOLISM; LIPID COMPOSITION; LIPID METABOLISM; METABOLIC DISORDER; MITOCHONDRIAL MEMBRANE PROTEIN ASSOCIATED NEURODEGENERATION; NERVE CELL; NERVE DEGENERATION; NERVOUS SYSTEM FUNCTION; NEURODEGENERATION WITH BRAIN IRON ACCUMULATION; NEUROLOGIC DISEASE; PHOSPHOLIPID METABOLISM; PLA2G6 ASSOCIATED NEURODEGENERATION; RARE DISEASE; RECESSIVE INHERITANCE; ANIMAL; BRAIN; CHEMISTRY; DEGENERATIVE DISEASE; GENETICS; IRON METABOLISM DISORDER; METABOLISM; MITOCHONDRION; NEUROAXONAL DYSTROPHY; SYNDROME;

ANIMALS; BRAIN; FATTY ACIDS; HUMANS; IRON; IRON METABOLISM DISORDERS; LIPID METABOLISM; MITOCHONDRIA; MIXED FUNCTION OXYGENASES; NEUROAXONAL DYSTROPHIES; NEURODEGENERATIVE DISEASES; PANTOTHENATE KINASE-ASSOCIATED NEURODEGENERATION; PHOSPHOLIPIDS; SPHINGOLIPIDS; SYNDROME;

EID: 84922079800     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-014-9770-z     Document Type: Article

References (113)

1. Alderson NL, Hama H (2009) Fatty acid 2-hydroxylase regulates cAMP-induced cell cycle exit in D6P2T Schwannoma cells. J Lipid Res 50:1203–8
2. Alderson NL, Rembiesa BM, Walla MD, Bielawska A, Bielawski J, Hama H (2004) The human FA2H gene encodes a fatty acid 2-hydroxylase. J Biol Chem 279:48562–48568
3. Alderson NL, Maldonado EN, Kern MJ, Bhat NR, Hama H (2006) FA2Hdependent fatty acid 2-hydroxylation in postnatal mouse brain. J Lipid Res 47:2772–2780
4. Bao S, Jacobson DA, Wohltmann M, Bohrer A, Jin W, Philipson LH, Turk J (2008) Glucose homeostasis, insulin secretion, and islet phospholipids in mice that overexpress iPLA2β in pancreatic β-cells and in iPLA2 β-null mice. Am J Physiol Endocrinol Metab 294:E217–E229
5. Basselin M, Rosa AO, Ramadan E, Cheon Y, Chang L, Chen M, Greenstein D, Wohltmann M, Turk J, Rapoport SI (2010) Imaging decreased brain docosahexaenoic acid metabolism and signaling in iPLA(2)beta (VIA)-deficient mice. J Lipid Res 51:3166–3173
6. Bayir H, Tyurin VA, Tyurina YY, Viner R, Ritov V, Amoscato AA, Zhao Q, Zhang XJ, Janesko-Feldman KL, Alexander H, Basova LV, Clark RS, Kochanek PM, Kagan VE (2007) Selective early cardiolipin peroxidation after traumatic brain injury: an oxidative lipidomics analysis. Ann Neurol 62:154–169
7. Beck G, Sugiura Y, Shinzawa K, Kato S, Setou M, Tsujimoto Y, Sakoda S, Sumi-Akamaru H (2011) Neuroaxonal dystrophy in calcium-independent phospholipase A2b deficiency results from insufficient remodeling and degeneration of mitochondrial and presynaptic membranes. J Neurosci 31:11411–11420
8. Beech DJ (2007) Bipolar phospholipid sensing by TRPC5 calcium channel. Biochem Soc Trans 35(1):101–104
9. Bolotina VM (2008) Orai, STIM1 and iPLA2β: a view from a different perspective. J Physiol 586(13):3035–3042
10. Bordet R, Ouk T, Petrault O et al (2006) PPAR: a new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans 34(Pt 6):1341–6
11. Bosetti F (2007) Arachidonic acid metabolism in brain physiology and pathology: lessons from genetically altered mouse models. J Neurochem 102(3):577–86
12. Bosveld F, Rana A, van der Wouden PE et al (2008) De novo CoA biosynthesis is required to maintain DNA integrity during development of the drosophila nervous system. Hum Mol Genet 17(13):2058–2069
13. Bousquet M, Gibrat C, Ouellet M, Rouillard C, Calon F, Cicchetti F (2010) Cystamine metabolism and brain transport properties: clinical implications for neurodegenerative diseases. J Neurochem 114:1651–8
14. Bras J, Singleton A, Cookson MR, Hardy J (2008) Emerging pathways in genetic Parkinson’s disease: potential role of ceramide metabolism in Lewy body disease. FEBS J 275:5767–5773
15. Brown HA, Murphy RC (2009) Working towards an exegesis for lipids in biology. Nat Chem Biol 5(9):602–606
16. Brunetti D, Dusi S, Morbin M et al (2012) Pantothenate kinase-associated neurodegeneration: altered mitochondria membrane potential and defective respiration in Pank2 knock-out mouse model. Hum Mol Genet 21:5294–305
17. Brunetti D, Dusi S, Giordano C et al (2014) Effect of pantethine treatment in a pantothenate kinase-associated neurodegeneration mouse model. Brain 137(Pt 1):57–68
18. Burke JE, Dennis EA (2009) Phospholipase A2 structure/function, mechanism, and signaling. J Lipid Res 50(Suppl):S237–42
19. Carta M, Lanore F, Rebola N et al (2014) Membrane lipids tune synaptic transmission by direct modulation of presynaptic potassium channels. Neuron 81(4):787–99
20. Cheon Y, Kim HW, Igarashi M, Modi HR, Chang L, Ma K, Greenstein D, Wohltmann M, Turk J, Rapoport SI, Taha AY (2012) Disturbed brain phospholipid and docosahexaenoic acid metabolism in calcium-independent phospholipase A(2)-VIA (iPLA2-beta)-knockout mice. Biochim Biophys Acta 821(9):1278–86
21. Conquer JA, Tierney MC, Zecevic J et al (2000) Fatty acid analysis of blood plasma of patients with Alzheimer’s disease, other types of dementia, and cognitive impairment. Lipids 35(12):1305–12
22. Cossu G, Abruzzese G, Matta G et al (2014) Efficacy and safety of deferiprone for the treatment of pantothenate kinase-associated neurodegeneration (PKAN) and neurodegeneration with brain iron accumulation (NBIA): results from a four years follow-up. Parkinsonism Relat Disord 20(6):651–4
23. Dalleau S, Baradat M, Guéraud F, Huc L (2013) Cell death and diseases related to oxidative stress: 4-hydroxynonenal (HNE) in the balance. Cell Death Differ 20:1615–1630
24. Dan P, Edvardson S, Bielawski J, Hama H, Saada A (2011) 2-Hydroxylated sphingomyelin profiles in cells from patients with mutated fatty acid 2-hydroxylase. Lipids Health Dis 10:84
25. Dick KJ et al (2010) Mutation of FA2H underlies a complicated form of hereditary spastic paraplegia (SPG35). Hum Mutat 31:E1251–E1260
26. Dusi S, Valletta L, Haack TB et al (2013) Exome sequence reveals mutations in CoA synthase as a cause of neurodegeneration with brain iron accumulation. Am J Hum Genet 94(1):11–22
27. Eddlestone GT (1995) ATP-sensitive K channel modulation by products of PLA2 action in the insulin-secreting HIT cell line. Am J Physiol Cell Physiol 268:C181–C190
28. Edvardson S, Hama H, Shaag A et al (2008) Mutations in the fatty acid 2-hydroxylase gene are associated with leukodystrophy with spastic paraparesis and dystonia. Am J Hum Genet 83:643–648
29. Esposito G, Giovacchini G, Liow JS et al (2008) Imaging neuroinflammation in Alzheimer’s disease with radiolabeled arachidonic acid and PET. J Nucl Med 49(9):1414–21
30. Evans SJ, Prossin AR, Harrington GJ et al (2012) Fats and factors: lipid profiles associate with personality factors and suicidal history in bipolar subjects. PLoS One 7(1):e29297
31. Garcia M, Leonardi R, Zhang YM et al (2012) Germline deletion of pantothenate kinases 1 and 2 reveals the key roles for CoA in postnatal metabolism. PLoS One 7(7):e40871
32. Ginsberg L, Rafique S, Xuereb JH et al (1995) Disease and anatomic specificity of ethanolamine plasmalogen deficiency in Alzheimer’s disease brain. Brain Res 698(1–2):223–6
33. Gregory A, Hayflick SJ (2011) Genetics of neurodegeneration with brain iron accumulation. Curr Neurol Neurosci 11(3):254–61
34. Guo L, Zhou D, Pryse KM, Okunade AL, Su X (2010) Fatty acid 2-hydroxylase mediates diffusional mobility of raft-associated lipids, GLUT4 level, and lipogenesis in 3T3-L1 adipocytes. J Biol Chem 285:25438–47
35. Hama H (2012) Fatty acid 2-Hydroxylation in mammalian sphingolipid biology. Biochim Biophys Acta 1801(4):405–14
36. Hartig MB, Iuso A, Haack T et al (2011) Absence of an orphan mitochondrial protein, c19orf12, causes a distinct clinical subtype of neurodegeneration with brain iron accumulation. Am J Hum Genet 89:543–550
37. Hayflick SJ (2006) Neurodegeneration with brain iron accumulation: from genes to pathogenesis. Semin Pediatr Neurol 13(3):182–5
38. Hodson L, Eyles HC, McLachlan KJ et al (2014) Plasma and erythrocyte fatty acids reflect intakes of saturated and n-6 PUFA within a similar time frame. J Nutr 44(1):33–41
39. 2+ channel protein Orai1 in a process that correlates with inhibition of stimulated STIM1 oligomerization. Biochim Biophys Acta 1841(8):1210–6
40. Hong S, Gronert K, Devchand P, Moussignac R-L, Serhan CN (2003) Novel docosatrienes and 17S-resolvins generated from docosahexaenoic acid in murine brain, human blood and glial cells: autacoids in anti-inflammation. J Biol Chem 278:14677–14687
41. Horvath R, Holinski-Feder E, Neeve V et al (2012) A new phenotype of brain iron accumulation with dystonia, optic atrophy and peripheral neuropathy. Mov Disord 27(6):789–93
42. Innis SM (2000) The role of dietary n-6 and n-3 fatty acids in the developing brain. Dev Neurosci 22(5–6):474–80
43. Itoh K, Negishi H, Obayashi C, Hayashi Y, Hanioka K, Imai Y, Itoh H (1993) Infantile neuroaxonal dystrophy: immunohistochemical and ultrastructural studies on the central and peripheral nervous systems in infantile neuroaxonal dystrophy. Kobe J Med Sci 39:133–146
44. Iuso A, Sibon OCM, Gorza M, Heim K, Organisti C, Meitinger T, Prokisch H (2014) Impairment of Drosophila orthologs of the human orphan protein C19orf12 induces bang sensitivity and neurodegeneration. PLoS ONE 9(2):e89439
45. Jadoon A, Chiu CC, McDermott L et al (2012) Associations of polyunsaturated fatty acids with residual depression or anxiety in older people with major depression. J Affect Disord 136(3):918–25
46. Ji J, Kline AE, Amoscato A, Samhan-Arias AK, Sparvero LJ, Tyurin VA, Tyurina YY, Fink B, Manole MD, Puccio AM, Okonkwo DO, Cheng JP, Alexander H, Clark RS, Kochanek PM, Wipf P, Kagan VE, Bayir H (2012) Lipidomics identifies cardiolipin oxidation as a mitochondrial target for redox therapy ofbrain injury. Nat Neurosci 15:1407–1413
47. Johnson MA, Kuo YM, Westaway SK et al (2004) Mitochondrial localization of human PANK2 and hypotheses of secondary iron accumulation in pantothenate kinase-associated neurodegeneration. Ann N Y Acad Sci 1012:282–98
48. Kagan VE, Bayir HA, Belikova NA, Kapralov O, Tyurina YY, Tyurin VA, Jiang J, Stoyanovsky DA, Wipf P, Kochanek PM, Greenberger JS, Pitt B, Shvedova AA, Borisenko G (2009) Cytochrome c/cardiolipin relations in mitochondria: a kiss of death. Free Radic Biol Med 46:1439–1453
49. Khateeb S, Flusser H, Ofir R, Shelef I, Narkis G, Vardi G, Shorer Z, Levy R, Galil A, Elbedour K, Birk OS (2006) PLA2G6 mutation underlies infantile neuroaxonal dystrophy. Am J Hum Genet 79(5):942–8
50. Kimura S (1991) Terminal axon pathology in infantile neuroaxonal dystrophy. Pediatr Neurol 7:116–120
51. Kishimoto Y, Radin NS (1963) Occurrence of 2-hydroxy fatty acids in animal tissues. J Lipid Res 4:139–143
52. Köroğlu C, Seven M, Tolun A (2013) Recessive truncating NALCN mutation in infantile neuroaxonal dystrophy with facial dysmorphism. J Med Genet 50(8):515–20
53. Kota V, Hama H (2014) 2′-Hydroxy ceramide in membrane homeostasis and cell signaling. Adv Biol Regul 54:223–230
54. Kotzbauer PT, Truax AC, Trojanowski JQ, Lee VM (2005) Altered neuronal mitochondrial coenzyme A synthesis in neurodegeneration with brain iron accumulation caused by abnormal processing, stability, and catalytic activity of mutant pantothenate kinase 2. J Neurosci 19;25(3):689–98
55. Kruer MC, Paisan-Ruiz C, Boddaert N, Yoon MY, Hama H, Gregory A et al (2010) Defective FA2H leads to a novel form of neurodegeneration with brain iron accumulation (NBIA). Ann Neurol 68:611–61
56. Kuo YM, Duncan JL, Westaway SK et al (2005) Deficiency of pantothenate kinase 2 (Pank2) in mice leads to retinal degeneration and azoospermia. Hum Mol Genet 14(1):49–57
57. Kuo YM, Hayflick SJ, Gitschier J (2007) Deprivation of pantothenic acid elicits a movement disorder and azoospermia in a mouse model of pantothenate kinase-associated neurodegeneration. J Inherit Metab Dis 30(3):310–317
58. Kurian MA, Morgan NV, MacPherson L, Foster K, Peake D, Gupta R, Philip SG, Hendriksz C, Morton JE, Kingston HM, Rosser EM, Wassmer E, Gissen P, Maher ER (2008) Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN). Neurology 70:1623–9
59. Lamari F, Mochel F, Sedel F, Saudubray JM (2013) Disorders of phospholipids, sphingolipids and fatty acids biosynthesis: toward a new category of inherited metabolic diseases. J Inherit Metab Dis 36:411–425
60. Lauber K, Bohn E, Krober SM, Xiao YJ, Blumenthal SG, Lindemann RK et al (2003) Apoptotic cells induce migration of phagocytes via caspase-3-mediated release of a lipid attraction signal. Cell 113:717–30
61. Leoni V, Strittmatter L, Zorzi G et al (2012) Metabolic consequences of mitochondrial coenzyme A deficiency in patients with PANK2 mutations. Mol Genet Metab 105(3):463–71
62. Liu HM, Larson M, Mizuno Y (1974) An analysis of the ultrastructural findings in infantile neuroaxonal dystrophy (Seitelberger’s disease). Acta Neuropathol 27:201–213
63. Lopés-Vales R, Navarro X, Shimizu T, Baskakis C, Kokotos G, Constantinou-Kokotou V, Stephens D, Dennis EA, David S (2008) Intracellular phospholipase A2 group IVA and group VIA play important roles in Wallerian degeneration and axon regeneration after peripheral nerve injury. Brain 131:2620–2631
64. Mahadevan A, Santosh V, Gayatri N, Ratnavalli E, NandaGopal R, Vasanth A, Roy AK, Shankar SK (2000) Infantile neuroaxonal dystrophy and giant axonal neuropathy: overlap diseases of neuronal cytoskeletal elements in childhood? Clin Neuropathol 19:221–229
65. Maldonado EN, Alderson NL, Monje PV, Wood PM, Hama H (2008) FA2H is responsible for the formation of 2-hydroxy galactolipids in peripheral nervous system myelin. J Lipid Res 49(1):153–61
66. Malik I, Turk J, Mancuso DJ, et al (2008) Disrupted membrane homeostasis and accumulation of ubiquitinated proteins in a mouse model of infantile neuroaxonal dystrophy caused by PLA2G6 mutations Am J Pathol 172(2):406-16
67. Mapstone M, Cheema AK, Fiandaca MS et al (2014) Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 20(4):415–8
68. Morgan NV, Westaway SK, Morton JE, Gregory A, Gissen P, Sonek S, Cangul H, Coryell J, Canham N, Nardocci N, Zorzi G, Pasha S, Rodriguez D, Desguerre I, Mubaidin A, Bertini E, Trembath RC, Simonati A, Schanen C, Johnson CA et al (2006) PLA2G6, encoding a phospholipaseA2, is mutated neurodegenerative disorders with high brain iron. Nat Genet 38:752–754
69. Mulder C, Wahlund LO, Teerlink T (2003) Decreased lysophosphatidylcholine/phosphatidylcholine ratio in cerebrospinal fluid in Alzheimer’s disease. J Neural Transm 110(8):949–55
70. Nemazanyy I, Panasyuk G, Breus O et al (2006) Identification of a novel CoA synthase isoform, which is primarily expressed in the brain. Biochem Biophys Res Commun 341:995–1000
71. 2+-independent phospholipase A2 and protein kinase C-dependent phosphorylation of the α-subunit. J Biol Chem 274:2000–2008
72. Pandey V, Turm H, Bekenstein H, Shifman S, Kadener S (2013) A new in vivo model of pantothenate kinase-associated neurodegeneration reveals a surprising role for transcriptional regulation in pathogenesis. Front Cell Neurosci 7:146
73. Perry TL, Norman MG, Yong VW et al (1985) Hallervorden-Spatz disease: cysteine accumulation and cysteine dioxygenase deficiency in the globus pallidus. Ann Neurol 18(4):482–9
74. Pizzimenti S, Ciamporcero E, Daga M, Pettazzoni P, Arcaro A, Cetrangolo G, Minelli R, Dianzani C, Lepore A, Gentile F, Barrera G (2013) Interaction of aldehydes derived from lipid peroxidation and membrane proteins. Front Physiol 4:242
75. Pope S, Land JM, Heales SJ (2008) Oxidative stress and mitochondrial dysfunction in neurodegeneration; cardiolipin a critical target? Biochim Biophys Acta 1777:794–799
76. Potter KA, Kern MJ, Fullbright G, Bielawski J, Scherer SS, Yum SV, Li JJ, Cheng H, Han X, Venkata JK, Khan PAA, Rohrer B, Hama H (2011) Central nervous system dysfunction in a mouse model of FA2H deficiency. Glia 59:1009–1021
77. Quehenberger O, Armando AM, Brown AH et al (2010) Lipidomics reveals a remarkable diversity of lipids in human plasma. J Lipid Res 51(11):3299–305
78. Rabin O, Deutsch J, Grange E et al (1997) Changes in cerebral acyl-CoA concentrations following ischemia-reperfusion in awake gerbils. J Neurochem 68(5):2111–8
79. Rana A, Seinen E, Siudeja K et al (2010) Pantethine rescues a Drosophila model for pantothenate kinase-associated neurodegeneration. Proc Natl Acad Sci 107(15):6988–93
80. Reed TT (2011) Lipid peroxidation and neurodegenerative disease. Free Radic Biol Med 51:1302–1319
81. Ren D (2011) Sodium leak channels in neuronal excitability and rhythmic behaviors. Neuron 72:899–911
82. Rhee HW, Zou P, Udeshi ND et al (2013) Proteomic mapping of mitochondria in living cells via spatially restricted enzymatic tagging. Science 339(6125):1328–31
83. Ross BM, Seguin J, Sieswerda LE (2007) Omega-3 fatty acids as treatments for mental illness: which disorder and which fatty acid? Lipids Health Dis 6:21
84. Rouault TA (2013) Iron metabolism in the CNS: implications for neurodegenerative diseases. Nat Rev Neurosci 14(8):551–64
85. Schaefer EJ, Bongard V, Beiser AS et al (2006) Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: the Framingham heart study. Arch Neurol 63(11):1545–50
86. Schipper HM (2012) Neurodegeneration with brain iron accumulation - clinical syndromes and neuroimaging. Biochim Biophys Acta 1822(3):350–60
87. Schlame M (2008) Cardiolipin synthesis for the assembly of bacterial and mitochondrial membranes. J Lipid Res 49:1607–1620
88. Schneider SA, Bhatia KP (2010) Three faces of the same gene: FA2H links neurodegeneration with brain iron accumulation, leukodystrophies, and hereditary spastic paraplegias. Ann Neurol 68(5):575–7
89. Schneider SA, Dusek P, Hardy J et al (2013) Genetics and pathophysiology of neurodegeneration with brain iron accumulation (NBIA). Curr Neuropharmacol 11:59–79
90. Schon EA, Area-Gomez E (2013) Mitochondria-associated ER membranes in Alzheimer disease. Mol Cell Neurosci 55:26–36
91. Schulte EC, Claussen MC, Jochim A et al (2013) Mitochondrial membrane protein associated neurodegeneration: a novel variant of neurodegeneration with brain iron accumulation. Mov Disord 28(2):224–7
92. Schwab JM, Chiang N, Arita M et al (2007) Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447(7146):869–74
93. Seleznev K, Zhao C, Zhang XH, Song K, Ma ZA (2006) Calcium-independent phospholipase A2 localizes in and protects mitochondria during apoptotic induction by staurosporine. J Biol Chem 281:22275–22288
94. Sharon R, Goldberg MS, Bar-Josef I, Betensky RA, Shen J, Selkoe DJ (2001) Alpha-Synuclein occurs in lipid-rich high molecular weight complexes, binds fatty acids, and shows homology to the fatty acid-binding proteins. Proc Natl Acad Sci U S A 98(16):9110–5
95. Shinzawa K, Sumi H, Ikawa M, Matsuoka Y, Okabe M, Sakoda S, Tsujimoto Y (2008) Neuroaxonal dystrophy caused by group VIA phospholipase A2 deficiency in mice: a model of human neurodegenerative disease. J Neurosci 28:2212–2220
96. Sian-Hülsmann J, Mandel S, Youdim MB et al (2011) The relevance of iron in the pathogenesis of Parkinson’s disease. J Neurochem 118(6):939–57
97. Smani T, Zakharov SI, Csutora P et al (2004) A novel mechanism for the store-operated calcium influx pathway. Nat Cell Biol 6:113–120
98. Sonnino S, Aureli M, Grassi S, et al (2013) Lipid rafts in neurodegeneration and neuroprotection. Mol Neurobiol Epub ahead of print
99. 2+ signaling in astrocytes from mouse models of human infantile neuroaxonal dystrophy with mutated Pla2g6. Hum Mol Genet 21(12):2807–2814
100. Tatsuta T, Scharwey, Langer T (2014) Mitochondrial lipid trafficking. Trends Cell Biol 24(1):44–52
101. Timmermann L, Pauls KA, Wieland K et al (2010) Dystonia in neurodegeneration with brain iron accumulation: outcome of bilateral pallidal stimulation. Brain 133(Pt 3):701–12
102. Vacher P, McKenzie J, Dufy B (1989) Arachidonic acid affects membrane ionic conductances of GH3 pituitary cells. Am J Physiol Endocrinol Metab 257:E203–E211
103. Vance JE (2014) MAM (mitochondria-associated membranes) in mammalian cells: lipids and beyond. Biochim Biophys Acta 1841(4):595–609
104. +-independent phospholipase A2-dependent gating of TRPM8 by lysophospholipids. J Biol Chem 281:40174–40182
105. Wada H, Yasuda T, Miura I et al (2009) Establishment of an improved mouse model for infantile neuroaxonal dystrophy that shows early disease onset and bears a point mutation in Pla2g6. Am J Pathol 175(6):2257–63
106. Walter A, Korth U, Hilgert M et al (2004) Glycerophosphocholine is elevated in cerebrospinal fluid of Alzheimer patients. Neurobiol Aging 25(10):1299–303
107. Zhao Z, Zhang X, Zhao C, Choi J, Shi J et al (2010) Protection of pancreatic beta-cells by group VIA phospholipase A2-mediated repair of mitochondrial membrane peroxidation. Endocrinology 151:3038–3048
108. Zhao Z, Wang J, Zhao C, Bi W, Yue Z et al (2011) Genetic ablation of PLA2G6 in mice leads to cerebellar atrophy characterized by Purkinje cell loss and glial cell activation. PLoS One 6(10):e26991
109. Zhou B, Westaway SK, Levinson B et al (2001) A novel pantothenate kinase gene (PANK2) is defective in Hallervorden-Spatz syndrome. Nat Genet 28(4):345–9
110. Zhyvoloup A, Nemazanyy I, Babich A et al (2001) Molecular cloning of CoA synthase. The missing link in CoA biosynthesis. J Biol Chem 277(25):22107–10
111. Zhyvoloup A, Nemazanyy I, Panasyuk G et al (2003) Subcellular localization and regulation of coenzyme a synthase. J Biol Chem 278(50):50316–50321
112. Zöller I, Meixner M, Hartmann D, Bussow H, Meyer R, Gieselmann V, Eckhardt M (2008) Absence of 2-hydroxylated sphingolipids is compatible with normal neural development but causes late-onset axon and myelin sheath degeneration. J Neurosci 28:9741–975
113. Zorzi G, Zibordi F, Chiapparini L et al (2011) Iron-related MRI images in patients with pantothenate kinase-associated neurodegeneration (PKAN) treated with deferiprone: results of a phase II pilot trial. Mov Disord 6(9):1756–9